Research |

 Relevant Publications Archive

 

1

 

The following research publications were supported by the Centre:

1. Cancer: The Tumor-Driven Disease of the Host.
Janowitz T.
Cell Metab. 2018 Jul 3;28(1):5-6. doi: 10.1016/j.cmet.2018.06.016.
2. CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.
Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.
Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.
3. Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.
Zaccagna F, Grist JT, Deen SS, Woitek R, Lechermann LM, McLean MA, Basu B, Gallagher FA.
EBr J Radiol. 2018 May;91(1085):20170688. doi: 10.1259/bjr.20170688. Epub 2018 Jan 19. Review.
4. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.
Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.
5. Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.
Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.
Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.
6. Pancreatic allograft thrombosis: Suggestion for a CT grading system and management algorithm.
Hakeem A, Chen J, Iype S, Clatworthy MR, Watson CJE, Godfrey EM, Upponi S, Saeb-Parsy K.
Am J Transplant. 2018 Jan;18(1):163-179. doi: 10.1111/ajt.14433. Epub 2017 Sep 14.
7. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.
Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.
Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. No abstract available.
8. Subclinical focal Cholangitis mimicking liver metastasis in asymptomatic patients with history of pancreatic Ductal Adenocarcinoma and Biliary tree intervention.
Horvat N, Godfrey EM, Sadler TJ, Hechtman JF, Tang LH, Sigel CS, Monti S, Mannelli L.
Cancer Imaging. 2017 Jul 14;17(1):21. doi: 10.1186/s40644-017-0124-6.
9. Connecting the Metabolic and Immune Responses to Cancer.
Flint TR, Fearon DT, Janowitz T.
Trends Mol Med. 2017 May;23(5):451-464. doi: 10.1016/j.molmed.2017.03.001. Epub 2017 Apr 7. Review.
10. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2. Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade. Xu R, Richards FM.
Comb Chem High Throughput Screen. 2017;20(5):451-457. doi: 10.2174/1386207320666170202093538. Review.
11. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.
Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, Ballard S, Lancaster J, Hamilton W, Rubin GP, Emery JD.
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):298-306. doi: 10.1016/S2468-1253(16)30079-6. Epub 2016 Oct 4.
12. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.
Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP.
Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6.
13. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.
J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.
14. The Role of the Single Incision Laparoscopic Approach in Liver and Pancreatic Resectional Surgery.
Chatzizacharias NA, Dajani K, Koong JK, Jah A.
Minim Invasive Surg. 2016;2016:1454026. Epub 2016 Nov 7. Review.
15. GEMMs as preclinical models for testing pancreatic cancer therapies.
Gopinathan A, Morton JP, Jodrell DI, Sansom OJ.
Dis Model Mech. 2015 Oct 1;8(10):1185-200. doi: 10.1242/dmm.021055. Review.
16. Scoring System to Predict Pancreatic Fistula After Pancreaticoduodenectomy: A UK Multicenter Study.
Roberts KJ, Sutcliffe RP, Marudanayagam R, Hodson J, Isaac J, Muiesan P, Navarro A, Patel K, Jah A, Napetti S, Adair A, Lazaridis S, Prachalias A, Shingler G, Al-Sarireh B, Storey R, Smith AM, Shah N, Fusai G, Ahmed J, Abu Hilal M, Mirza DF.
Ann Surg. 2015 Jun;261(6):1191-7. doi: 10.1097/SLA.0000000000000997.
17. Surgical intervention for mediastinal pancreatic pseudocysts. A case series and review of the literature.
Metaxa D, Balakrishnan A, Upponi S, Huguet EL, Praseedom RK.
JOP. 2015 Jan 31;16(1):74-7. doi: 10.6092/1590-8577/2904.
18. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Metaxa D, Balakrishnan A, Upponi S, Huguet EL, Praseedom RK.
JOP. 2015 Jan 31;16(1):74-7. doi: 10.6092/1590-8577/2904.
19. Colonic and anal metastases from pancreato-biliary malignancies.
Ejtehadi F, Chatzizacharias NA, Brais RJ, Hall NR, Godfrey EM, Huguet E, Praseedom RK, Jah A.
World J Gastroenterol. 2014 Apr 7;20(13):3693-7. doi: 10.3748/wjg.v20.i13.3693.
20. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.
Br J Cancer. 2014 Jul 15; 111(2): 318-25.
21. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.
Proc Natl Acad Sci USA. 2013 Dec 10; 110(50): 20212-7.
22. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.
Gut. 2013 Sep 25. doi: 10.1136/gutjnl-2013-3055593.
23. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.
PLoS One. 2013 Jun 28;8(6):e67330
24. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30.
25. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.
Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC.
Mol Biosyst. 2012 Oct 30;8(12):3125-33.
26. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.
Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.
Br J Cancer. 2012 Nov 6;107(10):1692-701.
27. Progress in pancreatic cancer: moving beyond gemcitabine?
Basu B, Jodrell D.
Expert Rev Anticancer Ther. 2012 Aug;12(8):997-1000.
28. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson DA.
Nature. 2012 Apr 29;486(7402):266-70.
29. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA, Chan DS, Neessee A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.
Gut. 2012 Mar 30
30. nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK, Neesse A, Cook N, Bapiro T, Lolkema MP, Jodrell DI, Tuveson DA.
Cancer Discovery. 2012
31. Gamma Secretase inhibition promotes hypoxic necrosis in murine pancreatic ductal adenocarcinoma.
Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T,
Howat WT, Jodrell DI, Tuveson DA.
J Exp Med. 2012 Mar 12;209(3):437-44.
32. A novel method for quantification of gemcitabine and its metabolites 2’,2’- difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.
Cancer Chemother Pharmacol. 2011 Nov; 68(5): 1243-53.
33. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson
DA.Nature. 2011 Jul 6;475(7354):106-9.